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Insights into frequent asthma exacerbations from a primary
care perspective and the implications of UK National Review
of Asthma Deaths recommendations
Jieqiong Freda Yang1, Rekha Chaudhuri1, Neil C. Thomson1, Nitish Ramparsad2, Hugh O’Pray3, Stephen Barclay4,
Sean MacBride-Stewart 5, Craig McCallum1, Varun Sharma1, Charles McSharry1, Dianne Murray1, Malcolm Shepherd1 and
Wai-Ting Nicola Lee1
The United Kingdom National Review of Asthma Deaths (NRAD) recommends that patients who require ≥3 courses of oral
corticosteroids (OCS) for exacerbations in the past year or those on British Thoracic Society (BTS) Step 4/5 treatment must be
referred to a specialist asthma service. The aim of the study was to identify the proportion of asthma patients in primary care that
fulﬁl NRAD criteria for specialist referral and factors associated with frequent exacerbations. A total of 2639 adult asthma patients
from 10 primary care practices in Glasgow, UK were retrospectively studied between 2014 and 2015. Frequent exacerbators and
short-acting β2-agonist (SABA) over-users were identiﬁed if they received ≥2 conﬁrmed OCS courses for asthma and ≥13 SABA
inhalers in the past year, respectively. Community dispensing data were used to assess treatment adherence deﬁned as taking
≥75% of prescribed inhaled corticosteroid (ICS) dose. The study population included 185 (7%) frequent exacerbators, 137 (5%) SABA
over-users, and 319 (12%) patients on BTS Step 4/5 treatment. Among frequent exacerbators, 41% required BTS Step 4/5 treatment,
46% had suboptimal ICS adherence, 42% had not attended an asthma review in the past year and 42% had no previous input from
a specialist asthma service. Older age, female gender, BTS Step 4/5, SABA over-use and co-existing COPD diagnosis increased the
risk of frequent exacerbations independently. Fourteen per 100 asthma patients would fulﬁl the NRAD criteria for specialist referral.
Better collaboration between primary and secondary care asthma services is needed to improve chronic asthma care.
npj Primary Care Respiratory Medicine  (2018) 28:35 ; doi:10.1038/s41533-018-0103-9
INTRODUCTION
Asthma is the most prevalent chronic respiratory disease in the
world affecting an estimated 358 million people in 2015.1 The
prevalence of asthma is high in the United Kingdom compared to
many other countries,2 ranging from 29.5% (18.5 million people)
for lifetime symptoms suggestive of asthma to 5.7% (3.6 million
people) for those with active, clinician-diagnosed-and-treated
asthma.3 United Kingdom has the third highest death rates for
asthma in high-income countries worldwide.4 Asthma generates a
considerable workload in general practice, with some estimated
2.7 million GP consultations, 3.7 million nurse consultations and
54,000 out-of-hours calls for asthma in 2011–2012.3 The annual
costs of asthma are estimated to be at least £1.1 billion with the
majority incurred in primary care and ~10% in secondary care.
There were 1370 asthma deaths across the United Kingdom in
2016, among them 133 in Scotland (data from National Records of
Scotland) and 1237 in England and Wales (data collected from
Ofﬁce for National Statistics in England and Wales).
It is over 40 years since the ﬁrst studies on asthma deaths in the
United Kingdom were published in the 1970s.5–7 Despite the
expansion of effective asthma treatment and development of
evidence-based management guidelines such as those from
British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines
Network (SIGN) and Global Initiative for Asthma (GINA),4,8 asthma
continues to cause signiﬁcant morbidity and unacceptably high
mortality rates. Avoidable factors preceding deaths were repeat-
edly identiﬁed in UK regional investigations into asthma deaths.9
In 2014, the Royal College of Physicians UK published the National
Review of Asthma Deaths (NRAD) report, ‘Why asthma still kills’.10
This was the ﬁrst and largest national investigation of asthma
deaths in the United Kingdom to establish the effectiveness of
asthma management, identify potential avoidable factors and
make recommendations to reduce the number of preventable
deaths. NRAD requested information on 900 asthma deaths coded
according to International Statistical Classiﬁcation of Diseases and
Related Health Problems 10th Revision between February 2012
and January 2013 in England, Wales and Scotland. A total of 740
patient records were returned and evaluated. After excluding 39%
who were not asthma deaths, 276 possible asthma deaths were
considered in detail by the conﬁdential enquiry panels. One
hundred ninety-ﬁve (70%) of those cases were conﬁrmed as
asthma deaths. The key ﬁndings were that the overall asthma
management in primary and secondary care was considered good
in less than one-ﬁfth of those who died. Potentially avoidable
factors were identiﬁed in two-thirds of cases. These ﬁndings led to
19 key recommendations related to the organisation of NHS
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services, medical and professional care, prescribing and medicines
use, patient factors and perception of risk. These include patients
must be referred to a specialist asthma service if they required ≥3
courses of systemic corticosteroids or ≥1 hospital admission in the
previous 12 months or BTS Step 4/5 treatment to achieve control.
These recommendations are similar to BTS/SIGN asthma guide-
lines, whereas GINA guidelines recommend referral in those who
have ≥2 exacerbations per year or uncontrolled symptoms despite
medium or high dose inhaled corticosteroids (ICS).4,8
The authors carried out an audit of asthma patients from ten
primary care practices in the North Greater Glasgow area over a
12-month period between 2014 and 2015. The aims of the audit
were ﬁrst to identify asthma patients with recurrent exacerbations
or on a high level of treatment who would merit referral to a
secondary care asthma service, and second to study the
biopsychosocial factors associated with frequent exacerbations.
RESULTS
Study cohort
A total of 48,462 patients were registered with the ten
participating primary care practices. A total of 4495 (9%) patients
had an asthma diagnosis. A total of 2639 (5%) patients received at
least one asthma reliever or preventer inhaler in the past
12 months and were included in the analysis as active asthma
patients. Among those, 185 patients (7%) required ≥2 courses of
oral corticosteroids (OCS) for asthma exacerbations in the past
12 months (frequent exacerbators). One hundred thirty-seven
(5%) were prescribed ≥13 short-acting β2-agonist (SABA) inhalers
in the past 12 months (SABA over-users). Three hundred nineteen
(12%) were on BTS Step 4/5 treatment. A&E attendance or hospital
admission was reported in 1.2% of patients. A total of 1724 (65%)
had at least one of the recorded comorbidities including chronic
obstructive pulmonary disease (COPD), diabetes, coronary heart
disease, hypertension, eczema, rhinitis, gastro–oesophageal reﬂux
disease, history of anxiety or depression and osteoporosis. Five
hundred ninety-two (22%) were current smokers. Two hundred
eighty-nine (11%) had a co-existing diagnosis of COPD. In this
group, 22% were frequent exacerbators, 13% were SABA over-
users and 43% were on BTS step 4/5 treatment. Characteristics of
all active asthma patients are shown in Table 1. Characteristics of
patients with co-existing asthma and COPD diagnoses are shown
in Table 2. Characteristics of patients with asthma and no co-
existing COPD diagnosis are shown in Table 3. Prevalence rates of
frequent exacerbators and SABA over-users by practice are shown
in Table 4.
Frequent exacerbators
Among 185 frequent exacerbators, 98 (53%) received two OCS
prescriptions, 39 (21%) received three OCS prescriptions and 48
(26%) received four OCS prescriptions for asthma in the past
12 months. Compared to non-frequent exacerbators, they were
older (mean age 57 ± 16 years vs 48 ± 17 years, p < 0.001), more
likely to be female (68% vs 58%, p= 0.006) or ever-smokers (62%
vs 48%, p= 0.001), and more likely to have adult-onset asthma
(91% vs 82%, p= 0.005) (Table 1). A greater proportion had a co-
existing diagnosis of COPD (35% vs 9%, p < 0.001). Other
comorbidities including diabetes (13% vs 6%, p= 0.001), coronary
heart disease (13% vs 6%, p= 0.001), hypertension (26% vs 19%, p
= 0.026), history of depression (31% vs 22%, p= 0.011) and
osteoporosis (9% vs 4%, p= 0.008) were more common. They
were more likely to have at least one comorbidity (84% vs 64%, p
< 0.001). A greater proportion of them were on BTS Step 4/5
treatment (41% vs 10%, p < 0.001) and were SABA over-users (14%
vs 5%, p < 0.001). Three per cent of frequent exacerbators did not
receive a prescription for ICS in the past 12 months. Forty-six per
cent of those on ICS were taking <75% of prescribed ICS dose.
Forty-two per cent had not attended an asthma review in primary
care in the past 12 months. Forty-two per cent had no previous
input from a specialist asthma service.
SABA over-users
Among the 137 SABA over-users, 119 (86%) used between one
and two SABA inhalers per month, 14 (10%) used between two
and three SABA inhalers per month, and 4 (3%) used more than
three SABA inhalers per month. Compared to patients using ≤12
SABA inhalers per year, they were older (mean age 52 ± 16 years
vs 48 ± 16 years, p= 0.016) and more likely to be ever-smokers
(73% vs 48%, p < 0.001) (Table 1). A greater proportion had a co-
existing diagnosis of COPD (26% vs 10%, p < 0.001). Other
comorbidities including diabetes (12% vs 7%, p= 0.013), history
of depression (41% vs 22%, p < 0.001) and osteoporosis (10% vs
4%, p= 0.008) were more common. They were more likely to have
at least one comorbidity (81% vs 64%, p < 0.001). A greater
proportion of them were on BTS Step 4/5 treatment (22% vs 12%,
p < 0.001) and were frequent exacerbators (18% vs 6%, p < 0.001).
Seven per cent had not received a prescription for ICS in the past
12 months. Forty-four per cent had not attended an asthma
review in primary care in the past 12 months.
Predictors of asthma exacerbations
A multivariable logistic regression model was ﬁtted to analyse the
association between covariates and incident frequent exacerba-
tions as a binary outcome. Independent predictors found to be
signiﬁcant were age, gender, BTS treatment step, SABA over-use
and co-existing COPD diagnosis (Table 5). There was signiﬁcant
interaction between age and co-existing COPD diagnosis (p value
for interaction= 0.029) (Table 6), with evidence for increased
exacerbation risk in older patients without a co-existing COPD
diagnosis, but no association between frequent exacerbations and
age in patients with a co-existing COPD diagnosis. There was no
evidence of interactions between COPD status and gender, BTS
treatment step or SABA over-use.
DISCUSSION
This is an observational study of asthma patients in an unselected
primary care population using routine clinical data extracted from
GP databases. It provided an estimate of the number of frequent
exacerbators, SABA over-users and patients requiring BTS Step 4/5
treatment in a city population of patients having received at least
one asthma reliever or preventer inhaler in the past 12 months. In
the study population, 7% were frequent exacerbators, 5% were
SABA over-users and 12% were on BTS Step 4/5 treatment.
Fourteen per cent of primary care patients with active asthma
would fulﬁl the NRAD and BTS/SIGN criteria for specialist asthma
referral. Sixteen per cent would fulﬁl GINA criteria for specialist
asthma referral. Among frequent exacerbators, there was a high
prevalence of modiﬁable factors such as cigarette smoking, SABA
over-use, treatment non-adherence and lack of regular asthma
review. Multiple comorbidities were common. Older age, female
gender, BTS Step 4/5, SABA over-use and co-existing COPD
diagnosis increased the risk of frequent exacerbations
independently.
The age, gender, smoking status, proportion of patients not
requiring ICS and comorbidities of the study population were in
general comparable to the demographic and clinical character-
istics of the UK asthma population reported by several large
studies using routine clinical data in primary care.11–13 There are
differences where relevant data are available for comparison. The
ethnicity of our study population was predominately white,
whereas other ethnic groups were included in an analysis of
primary care records in East London.11 The proportion of patients
with difﬁcult asthma (BTS Step 4/5 treatment) in our total study
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Table 1. Characteristics of all active asthma patients
All patients
(n= 2639)
Non-exacerbators
(n= 2454)
Exacerbators
(n= 185)
p value SABA ≤12 per year
(n= 2502)
SABA over-users
(n= 137)
p value
Age
Mean ± SD 48.5 ± 17.4 47.8 ± 17.4 56.9 ± 16.1 p < 0.001 48.3 ± 17.5 51.7 ± 15.6 p= 0.016
Sex
Female (%)
Male (%)
1538 (58.3%)
1100 (41.7%)
1412 (57.6%)
1041 (42.4%)
126 (68.1%)
59 (31.9%)
p= 0.006 1464 (58.5%)
1037 (41.5%)
74 (54.0%)
63 (46.0%)
p= 0.339
Age of onset (years)
<18 (%)
≥18 (%)
449 (17.0%)
2190 (83.0%)
432 (17.6%)
2022 (82.4%)
17 (9.2%)
168 (90.8%)
p= 0.005 423 (16.9%)
2079 (83.1%)
26 (19.0%)
111 (81.0%)
p= 0.609
Duration of asthma (years)
Mean ± SD 19.3 ± 15.2 19.4 ± 15.3 19.2 ± 14.2 p= 0.866 19.2 ± 15.3 21.3 ± 12.4 p= 0.065
Smoking status
Current smoker (%)
Ex-smoker (%)
Never smoked (%)
592 (22.4%)
699 (26.5%)
1348 (51.1%)
542 (22.1%)
635 (25.9%)
1277 (52.0%)
50 (27.0%)
64 (34.6%)
71 (38.4%)
p= 0.001 541 (21.6%)
650 (26.0%)
1311 (52.4%)
51 (37.2%)
49 (35.8%)
37 (27.0%)
p < 0.001
Comorbidities
COPD (%)
Diabetes (%)
CHD (%)
Hypertension (%)
Eczema (%)
GORD (%)
Rhinitis (%)
History of depression (%)
History of anxiety (%)
Osteoporosis (%)
289 (11.0%)
179 (6.8%)
176 (6.7%)
514 (19.5%)
253 (9.6%)
216 (8.2%)
476 (18.0%)
607 (23.0%)
265 (10.0%)
117 (4.4%)
225 (9.2%)
155 (6.3%)
152 (6.2%)
466 (19.0%)
243 (9.9%)
200 (8.1%)
442 (18.0%)
550 (22.4%)
247 (10.1%)
101 (4.1%)
64 (34.6%)
24 (13.0%)
24 (13.0%)
48 (25.9%)
10 (5.4%)
16 (8.6%)
34 (18.4%)
57 (30.8%)
18 (9.7%)
16 (8.6%)
p < 0.001
p= 0.001
p= 0.001
p= 0.026
p= 0.051
p= 0.781
p= 0.921
p= 0.011
p= 1.000
p= 0.008
253 (10.1%)
162 (6.5%)
165 (6.6%)
490 (19.6%)
234 (9.4%)
202 (8.1%)
450 (18.0%)
551 (22.0%)
246 (9.8%)
104 (4.2%)
36 (26.3%)
17 (12.4%)
11 (8.0%)
24 (17.5%)
19 (13.9%)
14 (10.2%)
26 (19.0%)
56 (40.9%)
19 (13.9%)
13 (9.5%)
p < 0.001
p= 0.013
p= 0.482
p= 0.657
p= 0.099
p= 0.339
p= 0.733
p < 0.001
p= 0.142
p= 0.008
Number of comorbidities
0 (%)
1 (%)
2 (%)
3 (%)
4+ (%)
915 (34.7%)
875 (33.2%)
493 (18.7%)
233 (8.8%)
123 (4.7%)
886 (36.1%)
815 (33.2%)
434 (17.7%)
211 (8.6%)
108 (4.4%)
29 (15.7%)
60 (32.4%)
59 (31.9%)
22 (11.9%)
15 (8.1%)
p < 0.001 889 (35.5%)
835 (33.4%)
457 (18.3%)
210 (8.4%)
111 (4.4%)
26 (19.0%)
40 (29.2%)
36 (26.3%)
23 (16.8%)
12 (8.8%)
p < 0.001
BTS step at the end of study year
1 (%)
2 (%)
3 (%)
4 (%)
5 (%)
Unclear (%)
488 (18.5%)
749 (28.4%)
1056 (40.0%)
313 (11.9%)
6 (0.2%)
27 (1.0%)
483 (19.7%)
729 (29.7%)
972 (39.6%)
240 (9.8%)
3 (0.1%)
27 (1.1%)
5 (2.7%)
20 (10.8%)
84 (45.4%)
73 (39.5%)
3 (1.6%)
0 (0.0%)
p < 0.001 479 (19.1%)
716 (28.6%)
995 (39.8%)
284 (11.4%)
5 (0.2%)
23 (0.9%)
9 (6.6%)
33 (24.1%)
61 (44.5%)
29 (21.2%)
1 (0.7%)
4 (2.9%)
p < 0.001
ICS dose at the end of study year (BDP equivalent)
Low (%)
Medium (%)
High (%)
Not on ICS (%)
Unclear (%)
979 (37.1%)
674 (25.5%)
316 (12.0%)
438 (16.6%)
232 (8.8%)
946 (38.5%)
612 (24.9%)
242 (9.9%)
433 (17.6%)
221 (9.0%)
33 (17.8%)
62 (33.5%)
74 (40.0%)
5 (2.7%)
11 (5.9%)
p < 0.001 937 (37.5%)
630 (25.2%)
286 (11.4%)
429 (17.1%)
220 (8.8%)
42 (30.7%)
44 (32.1%)
30 (21.9%)
9 (6.6%)
12 (8.8%)
p < 0.001
Asthma review in past year
No (%)
Yes (%)
1245 (47.2%)
1394 (52.8%)
1168 (47.6%)
1286 (52.4%)
77 (41.6%)
108 (58.4%)
p= 0.135 1185 (47.4%)
1317 (52.6%)
60 (43.8%)
77 (56.2%)
p= 0.468
Exacerbators
No (%)
Yes (%)
2454 (93.0%)
185 (7.0%)
— — — 2342 (93.6%)
160 (6.4%)
112 (81.8%)
25 (18.2%)
p < 0.001
SABA over-users
No (%)
Yes (%)
2502 (94.8%)
137 (5.2%)
2342 (95.4%)
112 (4.6%)
160 (86.5%)
25 (13.5%)
p < 0.001 — — —
Deﬁnitions: Frequent exacerbators, ≥2 courses of oral corticosteroids (OCS) for asthma exacerbations in the past 12 months; SABA over-users, prescribed ≥13
SABA inhalers in the past 12 months
SD standard deviation, SABA short-acting β2-antagonist, COPD chronic obstructive pulmonary disease, CHD coronary heart disease, HBP hypertension, GORD
gastro–oesophageal reﬂux disease, BTS British Thoracic Society, ICS inhaled corticosteroids, BDP beclometasone diproprionate
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Table 2. Characteristics of patients with co-existing asthma and COPD diagnoses
All patients
(n= 289)
Non-exacerbators
(n= 225)
Exacerbators
(n= 64)
p value SABA ≤12 per year
(n= 253)
SABA over-users
(n= 36)
p value
Age
Mean ± SD 66.2 ± 11.8 66.8 ± 12.0 63.9 ± 11.0 p= 0.065 66.8 ± 11.7 62.1 ± 12.1 p= 0.036
Sex
Female (%)
Male (%)
167 (57.8%)
122 (42.2%)
129 (57.3%)
96 (42.7%)
38 (59.4%)
26 (40.6%)
p= 0.882 145 (57.3%)
108 (42.7%)
22 (61.1%)
14 (38.9%)
p= 0.801
Age of onset (years)
<18 (%)
≥18 (%)
13 (4.5%)
276 (95.5%)
10 (4.4%)
215 (95.6%)
3 (4.7%)
61 (95.3%)
p= 1.000 12 (4.7%)
241 (95.3%)
1 (2.8%)
35 (97.2%)
p= 0.918
Duration of asthma (years)
Mean ± SD 17.9 ± 15.1 17.4 ± 15.7 19.9 ± 12.7 p= 0.197 17.7 ± 15.4 19.8 ± 13.0 p= 0.365
Smoking status
Current smoker (%)
Ex-smoker (%)
Never smoked (%)
92 (31.8%)
157 (54.3%)
40 (13.8%)
70 (31.1%)
121 (53.8%)
34 (15.1%)
22 (34.4%)
36 (56.2%)
6 (9.4%)
p= 0.495 80 (31.6%)
137 (54.2%)
36 (14.2%)
12 (33.3%)
20 (55.6%)
4 (11.1%)
p= 0.877
Comorbidities
Diabetes (%)
CHD (%)
Hypertension (%)
Eczema (%)
GORD (%)
Rhinitis (%)
History of depression (%)
History of anxiety (%)
Osteoporosis (%)
37 (12.8%)
58 (20.1%)
110 (38.1%)
7 (2.4%)
27 (9.3%)
29 (10.0%)
79 (27.3%)
37 (12.8%)
44 (15.2%)
27 (12.0%)
45 (20.0%)
93 (41.3%)
6 (2.7%)
22 (9.8%)
23 (10.2%)
59 (26.2%)
30 (13.3%)
36 (16.0%)
10 (15.6%)
13 (20.3%)
17 (26.6%)
1 (1.6%)
5 (7.8%)
6 (9.4%)
20 (31.2%)
7 (10.9%)
8 (12.5%)
p= 0.524
p= 1.000
p= 0.041
p= 1.000
p= 0.809
p= 1.000
p= 0.430
p= 0.832
p= 0.560
29 (11.5%)
52 (20.6%)
102 (40.3%)
5 (2.0%)
26 (10.3%)
23 (9.1%)
63 (24.9%)
29 (11.5%)
38 (15.0%)
8 (22.2%)
6 (16.7%)
8 (22.2%)
2 (5.6%)
1 (2.8%)
6 (16.7%)
16 (44.4%)
8 (22.2%)
6 (16.7%)
p= 0.104
p= 0.663
p= 0.043
p= 0.212
p= 0.221
p= 0.229
p= 0.017
p= 0.104
p= 0.805
Number of comorbidities
0 (%)
1 (%)
2 (%)
3 (%)
4+ (%)
0 (0.0%)
66 (22.8%)
88 (30.4%)
84 (29.1%)
51 (17.6%)
0 (0.0%)
53 (23.6%)
64 (28.4%)
65 (28.9%)
43 (19.1%)
0 (0.0%)
13 (20.3%)
24 (37.5%)
19 (29.7%)
8 (12.5%)
p= 0.421 0 (0.0%)
61 (24.1%)
75 (29.6%)
73 (28.9%)
44 (17.4%)
0 (0.0%)
5 (13.9%)
13 (36.1%)
11 (30.6%)
7 (19.4%)
p= 0.576
BTS step at the end of study year
1 (%)
2 (%)
3 (%)
4 (%)
5 (%)
Unclear (%)
18 (6.2%)
26 (9.0%)
118 (40.8%)
123 (42.6%)
2 (0.7%)
2 (0.7%)
17 (7.6%)
24 (10.7%)
99 (44.0%)
82 (36.4%)
1 (0.4%)
2 (0.9%)
1 (1.6%)
2 (3.1%)
19 (29.7%)
41 (64.1%)
1 (1.6%)
0 (0.0%)
p= 0.002 17 (6.7%)
23 (9.1%)
105 (41.5%)
106 (41.9%)
1 (0.4%)
1 (0.4%)
1 (2.8%)
3 (8.3%)
13 (36.1%)
17 (47.2%)
1 (2.8%)
1 (2.8%)
p= 0.268
ICS dose at the end of study year (BDP equivalent)
Low (%)
Medium (%)
High (%)
Not on ICS (%)
Unclear (%)
40 (13.8%)
95 (32.9%)
124 (42.9%)
16 (5.5%)
14 (4.8%)
38 (16.9%)
78 (34.7%)
82 (36.4%)
15 (6.7%)
12 (5.3%)
2 (3.1%)
17 (26.6%)
42 (65.6%)
1 (1.6%)
2 (3.1%)
p < 0.001 37 (14.6%)
87 (34.4%)
106 (41.9%)
15 (5.9%)
8 (3.2%)
3 (8.3%)
8 (22.2%)
18 (50.0%)
1 (2.8%)
6 (16.7%)
p= 0.004
Asthma review in past year
No (%)
Yes (%)
111 (38.4%)
178 (61.6%)
87 (38.7%)
138 (61.3%)
24 (37.5%)
40 (62.5%)
p= 0.981 100 (39.5%)
153 (60.5%)
11 (30.6%)
25 (69.4%)
p= 0.394
Exacerbators
No (%)
Yes (%)
225 (77.9%)
64 (22.1%)
— — — 204 (80.6%)
49 (19.4%)
21 (58.3%)
15 (41.7%)
p= 0.005
SABA over-users
No (%)
Yes (%)
253 (87.5%)
36 (12.5%)
204 (90.7%)
21 (9.3%)
49 (76.6%)
15 (23.4%)
p= 0.005 — — —
Deﬁnitions: Frequent exacerbators, ≥2 courses of oral corticosteroids (OCS) for asthma exacerbations in the past 12 months; SABA over-users, prescribed ≥13
SABA inhalers in the past 12 months
SD standard deviation, SABA short-acting β2-antagonist, COPD chronic obstructive pulmonary disease, CHD coronary heart disease, HBP hypertension, GORD
gastro–oesophageal reﬂux disease, BTS British Thoracic Society, ICS inhaled corticosteroids, BDP beclometasone diproprionate
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Table 3. Characteristics of patients with asthma and no co-existing COPD diagnosis
All patients
(n= 2350)
Non-exacerbators
(n= 2229)
Exacerbators
(n= 121)
p value SABA ≤12 per year
(n= 2249)
SABA over-users
(n= 101)
p value
Age
Mean ± SD 46.3 ± 16.7 45.9 ± 16.6 53.2 ± 17.1 p < 0.001 46.2 ± 16.8 47.9 ± 15.0 p= 0.268
Sex
Female (%)
Male (%)
1371 (58.4%)
978 (41.6%)
1283 (57.6%)
945 (42.4%)
88 (72.7%)
33 (27.3%)
p= 0.001 1319 (58.7%)
929 (41.3%)
52 (51.5%)
49 (48.5%)
p= 0.183
Age of onset (years)
<18 (%)
≥18 (%)
436 (18.6%)
1914 (81.4%)
422 (18.9%)
1807 (81.1%)
14 (11.6%)
107 (88.4%)
p= 0.056 411 (18.3%)
1838 (81.7%)
25 (24.8%)
76 (75.2%)
p= 0.132
Duration of asthma (years)
Mean ± SD 19.5 ± 15.2 19.6 ± 15.2 18.8 ± 15.0 p= 0.598 19.4 ± 15.3 21.8 ± 12.2 p= 0.059
Smoking status
Current smoker (%)
Ex-smoker (%)
Never smoked (%)
500 (21.3%)
542 (23.1%)
1308 (55.7%)
472 (21.2%)
514 (23.1%)
1243 (55.8%)
28 (23.1%)
28 (23.1%)
65 (53.7%)
p= 0.863 461 (20.5%)
513 (22.8%)
1275 (56.7%)
39 (38.6%)
29 (28.7%)
33 (32.7%)
p < 0.001
Comorbidities
Diabetes (%)
CHD (%)
Hypertension (%)
Eczema (%)
GORD (%)
Rhinitis (%)
History of depression (%)
History of anxiety (%)
Osteoporosis (%)
142 (6.0%)
118 (5.0%)
404 (17.2%)
246 (10.5%)
189 (8.0%)
447 (19.0%)
528 (22.5%)
228 (9.7%)
73 (3.1%)
128 (5.7%)
107 (4.8%)
373 (16.7%)
237 (10.6%)
178 (8.0%)
419 (18.8%)
491 (22.0%)
217 (9.7%)
65 (2.9%)
14 (11.6%)
11 (9.1%)
31 (25.6%)
9 (7.4%)
11 (9.1%)
28 (23.1%)
37 (30.6%)
11 (9.1%)
8 (6.6%)
p= 0.016
p= 0.050
p= 0.018
p= 0.358
p= 0.608
p= 0.235
p= 0.033
p= 1.000
p= 0.051
133 (5.9%)
113 (5.0%)
388 (17.3%)
229 (10.2%)
176 (7.8%)
427 (19.0%)
488 (21.7%)
217 (9.6%)
66 (2.9%)
9 (8.9%)
5 (5.0%)
16 (15.8%)
17 (16.8%)
13 (12.9%)
20 (19.8%)
40 (39.6%)
11 (10.9%)
7 (6.9%)
p= 0.201
p= 1.000
p= 0.789
p= 0.044
p= 0.088
p= 0.797
p < 0.001
p= 0.609
p= 0.035
Number of comorbidities
0 (%)
1 (%)
2 (%)
3 (%)
4+ (%)
915 (38.9%)
809 (34.4%)
405 (17.2%)
149 (6.3%)
72 (3.1%)
886 (39.7%)
762 (34.2%)
370 (16.6%)
146 (6.6%)
65 (2.9%)
29 (24.0%)
47 (38.8%)
35 (28.9%)
3 (2.5%)
7 (5.8%)
p < 0.001 889 (39.5%)
774 (34.4%)
382 (17.0%)
137 (6.1%)
67 (3.0%)
26 (25.7%)
35 (34.7%)
23 (22.8%)
12 (11.9%)
5 (5.0%)
p= 0.012
BTS step at the end of study year
1 (%)
2 (%)
3 (%)
4 (%)
5 (%)
Unclear (%)
470 (20.0%)
723 (30.8%)
938 (39.9%)
190 (8.1%)
4 (0.2%)
25 (1.1%)
466 (20.9%)
705 (31.6%)
873 (39.2%)
158 (7.1%)
2 (0.1%)
25 (1.1%)
4 (3.3%)
18 (14.9%)
65 (53.7%)
32 (26.4%)
2 (1.7%)
0 (0.0%)
p < 0.001 462 (20.5%)
693 (30.8%)
890 (39.6%)
178 (7.9%)
4 (0.2%)
22 (1.0%)
8 (7.9%)
30 (29.7%)
48 (47.5%)
12 (11.9%)
0 (0.0%)
3 (3.0%)
p= 0.011
ICS dose at the end of study year (BDP equivalent)
Low (%)
Medium (%)
High (%)
Not on ICS (%)
Unclear (%)
939 (40.0%)
579 (24.6%)
192 (8.2%)
422 (18.0%)
218 (9.3%)
908 (40.7%)
534 (24.0%)
160 (7.2%)
418 (18.8%)
209 (9.4%)
31 (25.6%)
45 (37.2%)
32 (26.4%)
4 (3.3%)
9 (7.4%)
p < 0.001 900 (40.0%)
543 (24.1%)
180 (8.0%)
414 (18.4%)
212 (9.4%)
39 (38.6%)
36 (35.6%)
12 (11.9%)
8 (7.9%)
6 (5.9%)
p= 0.007
Asthma review in past year
No (%)
Yes (%)
1134 (48.3%)
1216 (51.7%)
1081 (48.5%)
1148 (51.5%)
53 (43.8%)
68 (56.2%)
p= 0.361 1085 (48.2%)
1164 (51.8%)
49 (48.5%)
52 (51.5%)
p= 1.000
Exacerbators
No (%)
Yes (%)
2229 (94.9%)
121 (5.1%)
— — — 2138 (95.1%)
111 (4.9%)
91 (90.1%)
10 (9.9%)
p= 0.048
SABA over-users
No (%)
Yes (%)
2249 (95.7%)
101 (4.3%)
2138 (95.9%)
91 (4.1%)
111 (91.7%)
10 (8.3%)
p= 0.048 — — —
Deﬁnitions: Frequent exacerbators, ≥2 courses of oral corticosteroids (OCS) for asthma exacerbations in the past 12 months; SABA over-users, prescribed ≥13
SABA inhalers in the past 12 months
SD standard deviation, SABA short-acting β2-antagonist, COPD chronic obstructive pulmonary disease, CHD coronary heart disease, HBP hypertension, GORD
gastro–oesophageal reﬂux disease, BTS British Thoracic Society, ICS inhaled corticosteroids, BDP beclometasone diproprionate
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Table 4. Prevalence rates of frequent exacerbators and SABA over-users by practice
Total number of
registered patients
Active asthma
patients, number (%)
Frequent exacerbators in
each practice (%)
SABA over-users in
each practice (%)
Patients living in 15% most
deprived data zones in the SIMD
ranking (%)
Practice 1 5450 251 (5) 4 3 10.2
Practice 2 11,574 583 (5) 4 2 5.5
Practice 3 3144 170 (5) 6 4 18
Practice 4 4644 214 (5) 7 2 10.6
Practice 5 6714 349 (5) 7 5 34.4
Practice 6 2478 136 (5) 7 10 20.5
Practice 7 2224 144 (6) 8 8 70
Practice 8 3088 225 (7) 8 9 71.8
Practice 9 5061 293 (6) 8 9 58
Practice 10 4085 274 (7) 14 5 36.9
SABA short-acting beta-2 agonist, SIMD Scottish Index of Multiple Deprivation
Table 5. Logistic regression model for variables predicting frequent exacerbations (all patients)
Full model estimates Final model estimates
Odds ratio (95% CI); p value Odds ratio (95% CI); p value
Age (per 5 years) 1.08 (1.01, 1.14); p= 0.019 1.06 (1.01, 1.12); p= 0.020
Gender (male) 0.62 (0.43, 0.87); p= 0.006 0.64 (0.45, 0.89); p= 0.009
Asthma duration 1.00 (0.99, 1.01); p= 0.629 —
Ex-smoker
Never smoked
0.81 (0.53, 1.24); p= 0.331
0.89 (0.58, 1.37); p= 0.606
—
Diabetes (yes) 1.62 (0.96, 2.72); p= 0.071 —
CHD (yes) 1.07 (0.63, 1.84); p= 0.794 —
Hypertension (yes) 0.76 (0.50, 1.14); p= 0.182 —
Eczema (yes) 0.75 (0.38, 1.50); p= 0.414 —
GORD (yes) 0.88 (0.50, 1.56); p= 0.664 —
Rhinitis (yes) 1.26 (0.82, 1.92); p= 0.285 —
Depression (yes) 1.15 (0.80, 1.65); p= 0.463 —
Anxiety (yes) 0.70 (0.40, 1.20); p= 0.190 —
Osteoporosis (yes) 0.87 (0.47, 1.61); p= 0.647 —
BTS step (1/2/unclear)
BTS step (4/5)
0.43 (0.22, 0.82); p= 0.011
13.19 (1.70, 102.44); p= 0.014
0.29 (0.18, 0.46); p < 0.001
2.84 (1.97, 4.10); p < 0.001
ICS dose (medium)
ICS dose (high)
No ICS dose
Unclear ICS dose
1.34 (0.76, 2.38); p= 0.313
0.26 (0.03, 2.20); p= 0.218
0.50 (0.19, 1.35); p= 0.172
0.99 (0.46, 2.10); p= 0.971
—
SABA over-use (yes) 2.20 (1.30, 3.71); p= 0.003 2.35 (1.42, 3.89); p= 0.001
COPD (yes) 2.06 (1.34, 3.18); p= 0.001 2.01 (1.34, 3.01); p= 0.001
CHD coronary heart disease, GORD gastro–oesophageal reﬂux disease, BTS British Thoracic Society, ICS inhaled corticosteroids, SABA short-acting β2-antagonist,
COPD chronic obstructive pulmonary disease
Table 6. Logistic regression model for variables predicting frequent exacerbations (by co-existing COPD diagnosis status)
With co-existing COPD Without co-existing COPD p value for interaction
Odds ratio (95% CI); p value Odds ratio (95% CI); p value
Age (per 5 years) 0.94 (0.82, 1.06); p= 0.305 1.09 (1.03, 1.16); p= 0.003 0.029
Gender (male) 0.86 (0.47, 1.57); p= 0.629 0.56 (0.37, 0.85); p= 0.006 0.238
BTS step (1/2/unclear)
BTS step (4/5)
0.37 (0.10, 1.33); p= 0.129
2.60 (1.39, 4.88); p= 0.003
0.29 (0.18, 0.48); p < 0.001
2.94 (1.87, 4.63); p < 0.001
0.8635
SABA over-use (yes) 2.75 (1.26, 6.02); p= 0.011 1.89 (0.94, 3.84); p= 0.076 0.485
COPD chronic obstructive pulmonary disease, BTS British Thoracic Society, ICS inhaled crticosteroids, SABA short-acting β2-antagonist
Frequent asthma exacerbations in primary carey
JF Yang et al.
6
npj Primary Care Respiratory Medicine (2018)  35 Published in partnership with Primary Care Respiratory Society UK
population was higher (12%) than reported from the East London
study (~3%) and lower than reported from several UK national
databases (~23%).11,13,14 It is unclear if differences between the
cohorts reﬂect patient selection, differences in asthma service
delivery, implementation of asthma guidelines, treatment adher-
ence or disease severity. Nevertheless, we believe that the patients
with asthma included in this analysis are likely to be comparable
to most of the UK asthma population in primary care. The
prevalence rate of frequent exacerbators in the study population
of 7%, deﬁned as ≥2 OCS courses for asthma in the past year, was
comparable to rates reported in other large studies in the United
Kingdom.12,13 Several risk factors known to be associated with
frequent exacerbations in primary care12,14, including older age,
female gender, cigarette smoking, comorbidities and treatment
non-adherence, were more common in frequent exacerbators
compared to non-exacerbators in our asthma population.
Cigarette smoking in asthma is associated with worse clinical
outcomes.15 The 2016 Scottish Health Survey reported that one in
ﬁve adults (21%) in the general population were current cigarette
smokers16, a rate similar to the study population, although lower
than that in frequent exacerbators (27%). National smoking
cessation data published by Information Services Division Scot-
land showed that only 7% of smokers used the NHS smoking
cessation services across Scotland in 2015/16.17 The self-reported
quit rate was 37% at 1 month and 22% at 3 months. Respiratory
diagnosis is not captured in the database, so it is not known if the
usage of smoking cessation services and quit rates in asthmatics
differ from the general smoking population in Scotland. To
optimise smoking cessation intervention in asthmatic smokers,
more data on the smoking pattern, current uptake of NHS
smoking cessation services, quit rates and obstacles to quitting are
needed, especially in those with poorly uncontrolled symptoms
and frequent exacerbations. Smoking cessation remains a top
priority in this group.
ICS non-adherence is common and a major cause of poor
asthma outcomes. One study estimated 24% of asthma exacer-
bations were attributable to ICS non-adherence and exacerbation
rates were signiﬁcantly lower in patients taking ≥75% of
prescribed ICS dose.18 Only 54% of frequent exacerbators were
taking ≥75% of prescribed ICS dose in our study. Repeated
instruction on inhaler technique and self-management education
has been shown to improve adherence.19,20 Using objective
adherence measures such as prescription reﬁll records or
electronic dose monitoring would allow a more meaningful
concordance discussion between clinicians and patients. Common
factors of ICS non-adherence such as dissatisfaction with the
inhaler device, complex inhaler regime, fear of side effects and
lack of instruction are amenable to change.21 Medicine costs are
not a factor in treatment non-adherence in Scotland as prescrip-
tions are free, unlike other parts of the United Kingdom where
patients from low socio-economic backgrounds may be disad-
vantaged. Involvement of community pharmacists to deliver
inhaler technique checks, identify inappropriate use of inhalers
and promote smoking cessation would help to capture patients at
the point of use. Overuse of SABA inhalers is associated with poor
asthma control,22 increased risk of exacerbations,23,24 hospitalisa-
tion11 and death from asthma.10,25 Only 18% of SABA over-users
were frequent exacerbators. This suggests that a majority of SABA
over-users had persistent symptoms but were not prone to
exacerbations. Their excessive SABA use could be related to
psychological dependence on SABA inhalers, dysfunctional
breathing or psychological distress.26,27 Patients with a co-
existing COPD were more likely to over-use SABA inhalers (12%
vs 4% for patients without a co-existing COPD), and this may
reﬂect their need for more bronchodilator therapy. It is not known
how many SABA over-users were on a long-acting anti-muscarinic
inhaler. Seven per cent of SABA over-users were not on ICS and
31% were on low-dose ICS. This suggests that these patients
might not be on adequate preventer medication. They might not
have a personalised action plan or fully understand the rationale
of asthma medication leading to over-reliance on SABA inhalers to
control symptoms. Two key recommendations from NRAD were to
improve patient engagement with regular asthma review, in order
to reinforce the appropriate use of inhalers and self-management;
and to use electronic surveillance of prescribing to alert clinicians
to inappropriate reliever and preventer prescribing. Patients who
over-order SABA prescriptions and under-order ICS prescriptions
are most at risk of adverse outcomes and should be speciﬁcally
targeted for asthma review.
In this study, a majority of frequent exacerbators presented with
asthma symptoms after the age of 18 years. Previous studies
suggest that adult-onset asthma has distinct phenotypic char-
acteristics that are more related to environmental risk factors such
as cigarette smoking than early-onset asthma.28 NRAD data
suggest that adult-onset asthma may be a risk factor for asthma
deaths; 69% of deaths, for whom information was available,
occurred in patients diagnosed after the age of 15 years.10 More
research is needed to improve the understanding of the natural
history of adult-onset asthma and its pathophysiology in order to
better target new treatment and improve outcomes.
The commonly encountered problem of diagnostic uncertainty
in the management of asthma was highlighted by the number of
miscoded asthma deaths in the NRAD report. Out of 276 possible
asthma deaths, the conﬁdential enquiry panels concluded that
195 (71%) people died from asthma but 81 people did not have
asthma, had asthma but did not die from asthma, or there was not
enough information to make a decision. Out of the 195 cases that
had conﬁrmation of asthma deaths, 42 (22%) were considered by
their own clinicians to have COPD and asthma. Some asthma
deaths may have been missed (not included in the 195 cases)
because they were coded as COPD deaths. In addition, there was
no documented rationale for the diagnosis of asthma in 64 (33%)
of the 195 cases. One hundred (51%) of the 195 patients who died
were diagnosed on the basis of recurrent symptoms, 34 (17%) on
physiological measurement of lung function and 66 (34%) on the
response to asthma medication. In our study, we did not look into
the rationale for asthma diagnosis except in patients who had
attended the secondary care asthma clinic, so some patients
might have been misdiagnosed. For patients with co-existing
asthma and COPD diagnoses, it is unclear how many of them truly
had overlapping asthma and COPD or were simply miscoded
when one diagnosis replaced another without updating the
medical records. It is likely that some patients were miscoded. This
is a major limitation of using routine primary care data based on
disease coding. Clariﬁcation of diagnosis is one of the main
indications for referral to a specialist asthma service, universally
recommended by the NRAD report and other asthma guidelines.
A proportion of patients with asthma symptoms uncontrolled
by standard doses of asthma medication would have other factors
contributing to persistent symptoms. Failure to recognise and
modify these factors would result in inappropriate treatment
escalation and adverse outcomes as highlighted in the NRAD
report. One proposed strategy to improving the management of
asthma in primary care is SIMPLES.29 It provides a structured
approach to evaluate factors that inﬂuence asthma control
including smoking status (S), inhaler technique (I), monitoring
(M), pharmacotherapy (P), lifestyle (L), education (E) and support
(S). Patients who remain poorly controlled after applying this
structured review should then be referred to a specialist asthma
service for further diagnostic evaluation and consideration of
treatment escalation. Both NRAD and BTS/SIGN guidelines
recommend that patients should be followed up within 48 h of
each attendance for an acute asthma attack. This would reduce
the likelihood of patients re-attending for more treatment when
treatment runs out before the original attack is over. Moreover,
there is a need for closer collaboration between primary and
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secondary care clinicians. An integrated asthma care model was
tested in the Grampian Asthma Study of Integrated Care in the
1990s, in which chest physicians reviewed patients in outpatient
clinic annually and interim reviews took place in general
practice.30 Through a computer patient record system, patients
entered information about their symptoms, OCS courses and
hospital admissions. The GP entered information about SABA use,
OCS prescriptions and medication changes. The consultant would
review the records and suggest changes to treatment if necessary.
The study showed moderately severe asthma patients had similar
clinical outcomes compared to the conventional group. Patients
who had integrated care did beneﬁt ﬁnancially and considered
themselves to have a higher level of asthma control compared to
those who received conventional care. This model of integrated
care may be the way forward.
Strengths and limitations
There is currently no direct link between community dispensing
data to individual patient medical records stored in primary or
secondary care in the United Kingdom. Other UK studies had used
prescription data based on electronic prescriptions issued by GPs
to assess medication usage and treatment adherence.11–14 In this
study, we used real life dispensing data submitted by community
pharmacies for administrative purpose and linked them to
individual patients by their Community Health Index (CHI)
number, a unique 10-digit numeric identiﬁer allocated to each
patient on their ﬁrst registration with the health service in
Scotland. This would provide a more accurate evaluation of
treatment adherence by excluding non-dispensed prescriptions. A
major strength of this study is that each OCS prescription in
frequent exacerbators was manually checked against clinical
records to conﬁrm that it was prescribed for an asthma
exacerbation. This study has a number of limitations. Data on
body mass index were lacking, and as a result, we were not able to
explore the relationship between obesity and frequent exacerba-
tions. It is well recognised that obese asthmatics respond less well
to treatment, and this may have a negative impact on treatment
adherence.31 There was no record of whether an invitation letter
to asthma review had been sent or if patients had not attended
appointments made. The number of patients issued with a
personalised asthma action plan is not known.
The proportion of active asthma patients in a general primary
care population who would warrant specialist asthma referral was
estimated to be 14–16%. A high prevalence of modiﬁable factors
in patients with frequent exacerbations was identiﬁed. These
include cigarette smoking, SABA over-use, treatment non-
adherence and lack of regular asthma review, consistent with
the ﬁndings in the NRAD report. Independent predictors for
frequent exacerbations were found to age, gender, BTS treatment
step, SABA over-use and co-existing COPD diagnosis. There was
signiﬁcant interaction between age and co-existing COPD
diagnosis, with evidence for increased exacerbation risk in older
patients without a co-existing COPD diagnosis, but no association
between frequent exacerbations and age in patients with a co-
existing COPD diagnosis. It is clear that primary and secondary
specialist asthma services need to work more closely together to
provide integrated asthma care, in order to reduce exacerbations
and prevent asthma deaths. This could be achieved by employing
a structured approach to managing asthma patients in primary
care and referring those with diagnostic uncertainty or therapy-
resistant asthma to a specialist asthma service.
METHODS
Study cohort
Ten GP practices in North Glasgow were invited to participate in this
retrospective study of patients diagnosed with asthma in each practice
between 2014 and 2015. The study cohort was identiﬁed by searching
primary care EMIS-web databases for patients who had been coded with a
diagnosis of asthma using computer software by an IT specialist. The
process of how the study cohort was established is outlined in
supplementary information on 'Data Extraction from GP databases'. Data
on demographics (age, gender, age of onset and duration of asthma),
smoking history, comorbidities (COPD, diabetes, coronary heart disease,
hypertension, eczema, rhinitis, gastro–oesophageal reﬂux disease, history
of anxiety or depression and osteoporosis), inhaled therapy (BTS Step) and
number of OCS prescriptions were collected in patients aged ≥18 years
and those who received at least one asthma reliever or preventer inhaler
prescription in the past 12 months. Permission was obtained from
individual GP practices to identify patients from their practice who had
episodes of A&E attendance or hospital admission for asthma during the
study period and review related clinical information from secondary care.
Permission was granted from management of NHS Greater Glasgow &
Clyde Health Board to access this data. Acute Information Team of the NHS
Greater Glasgow & Clyde Health Board generated a list of patient episodes
covering the study period for each practice. Each patient was identiﬁed by
their CHI number. Each acute episode was identiﬁed by the date of
admission and date of discharge. The causes of admissions and A&E
attendances were checked against individual secondary care records.
Patients were identiﬁed as a frequent exacerbator if they had ≥2 acute OCS
courses for asthma exacerbations in the past 12 months. Prescription data
of each frequent exacerbator were individually examined to exclude OCS
prescribed for alternative diagnoses. Two courses of OCS prescribed within
1 week of each other were considered as one course of treatment.
Community dispensing data were extracted from NHS central dispensing
administrative data to assess treatment adherence in frequent exacer-
bators. The number of ICS prescriptions collected over a 12-month period
between 2014 and 2015 was counted to calculate the total ICS dose
(beclometasone diproprionate equivalent) received during this period. The
average daily ICS dose received was then calculated. Treatment adherence
was deﬁned as taking ≥75% of prescribed ICS dose. Patients who used ≥13
SABA inhalers in the past 12 months were grouped as SABA over-users. All
data were anonymised and managed in compliance with NHS Caldicott
Guardian principles.
Statistical analysis
Continuous data were summarised as mean ± standard deviation and
compared using unpaired Student’s t test. Categorical data were
summarised as number (%) and compared by Fisher’s exact test. A
multivariable logistic regression model was ﬁtted to further analyse the
association between covariates and frequent exacerbations as a binary
outcome. All covariates were entered into a manual backward selection
procedure, in which covariates were sequentially removed if they failed to
provide an improvement in model ﬁt at a threshold of p < 0.05; at each
step the covariate with the largest p value was removed. Covariates
signiﬁcant in predicting frequent exacerbations were age, gender, BTS
treatment step, SABA over-use and co-existing COPD diagnosis. Both the
full model and that of the ﬁnal model odds ratio, 95% conﬁdence interval
(CI) and p values are shown in Table 5. The ﬁnal model was then extended
to include all two-way interactions with co-existing COPD diagnosis. Odds
ratios for frequent exacerbations were estimated for those with and
without a co-existing COPD diagnosis and are reported with 95% CI, p
values, along with p value for each interaction term in this model (Table 6).
All analyses were performed using the statistical software R version 3.1.2.
(ref. 32)
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